4Basebio PLCLSE 4Basebio Stock Report

4basebio Plc develops gene therapy technologies and solutions. The firm is engaged in the design, manufacture and supply of application-specific synthetic deoxyribonucleic (DNA) or messenger ribonucleic acid (mRNA), as well as targeted non-viral vectors for the delivery of nucleic acid payloads. The firm is focused on supplying therapeutic DNA for gene therapies and gene-based vaccines and also providing solutions for the delivery of DNA-based products to patients. The firm focuses to manufacture and supplying synthetic DNA for research, therapeutic and pharmacological use. The company has technology in the fields of DNA synthesis and payload delivery, which enables it to manufacture both synthetic DNA constructs and mRNA and develop vectors for cell and tissue-specific delivery for a range of applications. Its applications include AAV and Lentivirus viral vectors; mRNA vaccines and therapeutics, Genome editing; DNA vaccines, and Hermes non-viral delivery.